Research interests
Publication: Accuracy of site versus core laboratory interpretations of right heart catheterization hemodynamics[5]
2026
DF
David Franklin Kong
Fellow in Cardiology at Duke University
As of 2001 · Last known relationship
Fellow in Cardiology at Duke University
As of 2001 · Last known relationship
David Franklin Kong is a Duke cardiovascular physician and research leader whose work connects interventional cardiology, clinical-trial evidence, medical-device evaluation, and healthcare informatics. He is an Associate Professor of Medicine at Duke University Medical Center, an interventional cardiologist at Duke Hospital, a member of the Duke Clinical Research Institute, and Co-Director of its Cardiovascular Late Phase 3 and Devices Unit. He is also faculty in the Duke Center for Healthcare Informatics. Kong graduated magna cum laude from Harvard University and earned a master’s degree in Organismic and Evolutionary Biology there. He received his M.D. from Johns Hopkins in 1993, completed residency there from 1993 to 1995, and was a Duke cardiology fellow from 1995 to 2001, including fellowships in cardiovascular disease and interventional cardiovascular medicine. He is board certified in internal medicine, cardiology, and interventional cardiology.
Each topic is linked to its supporting source in Sources.
Training includes Fellow in Cardiology at Duke University, Medical residency at Johns Hopkins University, Resident on the Osler Medical Service at Johns Hopkins Hospital, and Received a medical degree from Johns Hopkins University School of Medicine, plus 18 more records.
Explore education and trainingAs of 2001
As of 1995
As of 1995
As of 1993
Publication: Accuracy of site versus core laboratory interpretations of right heart catheterization hemodynamics[5]
2026
Publication: A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia[5]
2020
Publication: A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention[5]
2020
Publication: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure[5]
2021
Publication: Corrigendum to "Accuracy of Site versus Core Laboratory Interpretations of Right Heart Catheterization Hemodynamics"[5]
2026
Publication: Corrigendum to: A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia[5]
2020
Publication: Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery[5]
2023
Publication: SCAI publications committee manual of standard operating procedures[5]
2020
Publication: Splanchnic Nerve Block for Chronic Heart Failure[5]
2020
Publication: The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease[5]
2021
Specializes in cardiovascular informatics research[5]
Specializes in integration of evidence from cardiovascular clinical trials[5]